Vir Biotechnology Inc reports results for the quarter ended March 31 - Earnings Summary

• Vir Biotechnology Inc VIR.OQ reported a quarterly adjusted loss of 88 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -48 cents. The mean expectation of seven analysts for the quarter was for a loss of 84 cents per share. Wall Street expected results to range from $-1.03 to -67 cents per share.

• Revenue fell 94.6% to $3.03 million from a year ago; analysts expected $8.59 million.

• Vir Biotechnology Inc's reported EPS for the quarter was a loss of 88 cents​.

• The company reported a quarterly loss of $120.97 million.

• Vir Biotechnology Inc shares had fallen by 13.4% this quarter and lost 23.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.5% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Vir Biotechnology Inc is $20.00

This summary was machine generated from LSEG data May 8 at 05:47 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)